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The human cytomegalovirus (HCMV) major immediate-early promoter (MIEP) is one of the first promoters
to activate upon infection. To examine HCMV MIEP tissue-specific expression, transgenic mice were estab-
lished containing the lacZ gene regulated by the MIEP (nucleotides 2670 to 154). In the transgenic mice, lacZ
expression was demonstrated in 19 of 29 tissues tested by histochemical and immunochemical analyses. These
tissues included brain, eye, spinal cord, esophagus, stomach, pancreas, kidney, bladder, testis, ovary, spleen,
salivary gland, thymus, bone marrow, skin, cartilage, and cardiac, striated and smooth muscles. Although
expression was observed in multiple organs, promoter activity was restricted to specific cell types. The cell types
which demonstrated HCMV MIEP expression included retinal cells of the eye, ductile cells of the salivary
gland, exocrine cells of the pancreas, mucosal cells of the stomach and intestine, neuronal cells of the brain,
muscle fibers, thecal cells of the corpus luteum, and Leydig and sperm cells of the testis. These observations
indicate that the HCMV MIEP is not a pan-specific promoter and that the majority of expressing tissues
correlate with tissues naturally infected by the virus in the human host.
Human cytomegalovirus (HCMV) is a betaherpesvirus with
a viral genome capable of encoding more than 200 proteins (6).
The genes encoding these proteins have been subdivided into
three kinetic classes which include immediate early (IE), early
(E), and late (L) (7, 57). The expression of the IE genes is
dependent on host cell factors, while both the early and late
genes are interdependent on viral and cellular factors. The
region of predominant IE expression occurs in two contiguous
areas designated IE-1 (UL123) and IE-2 (UL122) (6, 49–51).
Together, these two regions constitute the major IE (MIE)
gene which is regulated by the major IE promoter (MIEP).
The MIEP controls the expression of three predominant IE
protein isoforms (49, 51). The MIE proteins are transcriptional
regulatory factors which, together with host cell proteins, tem-
porally regulate subsequent viral gene expression (49). Since
these proteins play a pivotal role in determining the permissive
state of the virus, activation of the MIEP may be the critical
step in determining HCMV tissue-specific expression.
The MIEP is a complex regulatory element which is com-
posed of distinct domains, including a basal promoter with a
canonical TATA box (14) and a strong enhancer between
nucleotides (nt) 250 and 2530 (3, 55). Sequences between nt
2750 and21145 are known to repress the activity of the MIEP
in undifferentiated cells (25, 33, 34, 36, 44). In vitro studies
have shown that the enhancer appears to be universally func-
tional in multiple cell types (3, 19, 36, 41, 44, 48, 55).
Because HCMV is a species-specific virus, the mechanisms
involved in viral pathogenicity have been difficult to approach
in animal models. However, transgenic technology has pro-
vided a means to examine specific effects of viral proteins or
promoter regulatory elements in vivo. To date, two indepen-
dent HCMV enhancer transgenic mouse studies have reported
on tissue-specific expression of genes under the control of the
HCMV MIEP in adult mice (10, 43). Observations from these
groups suggest that the HCMV MIEP is a pan-specific pro-
moter. However, neither of these studies identified cell types
within tissues targeted for expression by the HCMV MIEP.
Recently, Koedood et al. (23) examined expression of the
HCMV MIEP during embryogenesis in transgenic mice. In
their studies, specific expression which was dependent on the
tissue and stage of fetal gestation was observed in embryos.
These observations suggest that HCMVMIEP expression dur-
ing embryogenesis is highly regulated by the developing tis-
sues.
In the present study, we examined tissue-specific expression
of the HCMVMIEP in adult transgenic mice. The specific cell
types within organs were also assessed histochemically and
immunochemically for expression. Our results indicate that the
enhancer domain of the MIEP targets expression in 19 of the
29 organs examined. Although expression was detected in mul-
tiple organ systems, promoter activity within these tissues was
restricted to specific cell types. The majority of these tissues
correlated with tissues naturally infected by HCMV in the
human host. These observations indicate that the HCMV
MIEP is not a pan-specific promoter and that expression in
transgenic mice is restricted to specific cells.
* Corresponding author. Mailing address: Department of Molecular
Microbiology and Immunology, Oregon Health Sciences University
School of Medicine, 3181 S.W. Sam Jackson Park Rd., Portland, OR
97201. Phone: (503) 494-7769. Fax: (503) 494-2441. Electronic mail
address: nelsonj@ohsu.edu.
† Present address: Roche Research Centre, Welwyn Garden City,
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MATERIALS AND METHODS
Construction and preparation of the MIEP-lacZ transgene. The MIEP-lacZ
transgene was generated by inserting the HCMV MIEP (nt 2670 to 154) as a
HindIII-EcoRI fragment from pRR49 (a generous gift from R. Ruger) into p315
DNA (derived from pbactin P E1 IVS SDK lacZpA, a generous gift of R. Scott),
which contains a promoterless Escherichia coli lacZ gene (GenBank accession
no. V00296), starting downstream of a Shine-Delgarno sequence and a Kozak
consensus sequence and upstream of a simian virus 40 polyadenylation signal
sequence (BclI to BamHI, nt 2533 to 2770) (Fig. 1A). The resulting plasmid,
designated p324, was digested with restriction enzymes HindIII and SacII to
separate the MIEP-lacZ transgene from vector sequences prior to microinjec-
tion.
Generation of MIEP-lacZ transgenic mice. MIEP-lacZ transgenic mice were
generated by injection of linear DNA, purified after the removal of vector
sequences, into the male pronuclei of fertilized ova derived from FVB mice
(TG75ACP) or from CB6F2/J (TG1JB and TG2JB) mice as previously described
(17). After injection, ova were transferred to surrogate pseudopregnant FBV or
CB6F1/J mice for development and delivery. Transgenic mice generated by this
procedure were identified by Southern blot analysis (46) of high-molecular-
weight DNA extracted from tail biopsies of homozygous transgenic mice by using
the proteinase K-sodium dodecyl sulfate extraction procedure (17). Briefly, 10 mg
of genomic mouse DNA was digested with restriction enzyme PstI, which cuts
once in the transgene, or with PvuII, which cuts twice, to release a 2.5-kb
fragment, run on a 1% agarose gel, and transferred to GeneScreen Plus (E. I.
Dupont-NEN) by the method of Southern (46). The filters were then probed
with 32P-random primer-labeled MIEP-lacZ transgene, washed, and exposed to
X-ray film. Transgene copy number was estimated by comparing the digestion
pattern and band intensities of transgenic mouse DNAs with 1 or 10 genomic
equivalents of MIEP-lacZ transgene mixed with nontransgenic mouse genomic
DNA digested with the same enzyme. Founder lines were established from
transgenic mice that transmitted the MIEP-lacZ gene to progeny in Mendelian
fashion and demonstrated reproducible patterns of 5-bromo-4-chloro-3-indolyl-
b-D-galactopyranoside (X-Gal) staining in tissues over multiple generations.
Each transgenic line was inbred to homozygosity.
Histochemical and immunocytochemical analysis of lacZ transgene expres-
sion. To prepare transgenic mouse tissue for histochemical analysis, adult mice
were anesthetized with avertin and perfused with saline–4% paraformaldehyde.
After perfusion, tissues were removed and placed in freshly prepared 4% para-
formaldehyde for 4 h at 48C. Tissues were subsequently rinsed in phosphate-
buffered saline (PBS) containing 10% sucrose and frozen in OCT (Miles Scien-
tific, Elkhart, Ind.). Twenty-micrometer-thick frozen sections were cut on a
Reichert-Jung cryostat and stained with X-Gal (Sigma Chemical Corp., St. Louis,
Mo.) overnight at 48C (42). After staining, slides were rinsed in 0.1 M PBS,
counterstained with eosin, and dehydrated through increasing concentrations of
isopropyl alcohol. After brief immersion in xylene, slides were coverslipped with
permount and examined under a light microscope.
For immunohistochemical analysis, tissues were fixed as above and embedded
in paraffin. Ten-micrometer-thick sections were placed on gelatin-coated slides
and stained by the method of Nilaver and Kozlowski (37). Briefly, slides were
deparaffinized in Americlear (Baxter Sci., McGaw Park, Ill.), hydrated through
graded ethanol, rinsed in 0.05 M Tris containing 0.9% NaCl, pH 7.6 (hereafter
referred to as Tris-saline), and then treated with 1% hydrogen peroxide for 30
min. Slides were subsequently rinsed in Tris-saline to remove hydrogen peroxide
and incubated in Tris-saline plus 0.1% Triton X-100 (hereafter referred to as Tris
A) for 15 min to delipidate sections and permeabilize the cell membranes. Slides
were then incubated in Tris-saline with 0.1% Triton X-100–0.02% bovine serum
albumin (Sigma) (hereafter referred to as Tris B) for 15 min and exposed to
rabbit anti-b-galactosidase antibody (Organon Teknika, West Chester, Pa.) that
had been preabsorbed with mouse and rat liver powder (Sigma) at a 1:100
dilution in Tris B, at 48C for 12 h. After incubation, the slides were rinsed in Tris
A for 20 min and Tris B for 20 min and exposed to biotinylated protein A (Vector
Labs, Burlingame, Calif.) for 45 min at room temperature. Slides were rinsed and
exposed to ABC (Vector) for 1 h, and positive cells were visualized using
3-amino-9-ethyl carbazole (AEC) (Dako Corp., Carpintera, Calif.). Slides were
counterstained with Mayer’s hematoxylin, rinsed, dehydrated through isopropyl
alcohol, rinsed briefly in xylene, and coverslipped with permount.
An alternative immunohistochemical staining procedure was also performed
for detection of lacZ expression (38). In this method, transgenic mice were
perfused with 10% formalin, and tissues were fixed in 10% formalin for at least
3 days. Tissues were then embedded in gelatin-egg yolk, sectioned 100-mm thick
on a vibratome, and stored in Tris-saline. Sections were then treated with 1%
hydrogen peroxide for 30 min, rinsed in Tris-saline, and incubated in Tris A for
15 min, Tris B for 15 min, and anti-b-galactosidase antibody for 12 to 16 h at 48C.
Tissues were rinsed with Tris A and Tris B and incubated in biotinylated protein
A for 45 min at 258C, incubated in Tris A for 15 min, Tris B for 15 min, and ABC
for 1 h at 258C, and then rinsed in Tris-saline. Tissues were then exposed to
3,3-diaminobenzidine (DAB) (Sigma) for 15 to 45 min at 258C, rinsed with
Tris-saline, mounted on gelatin-coated slides, air dried, dehydrated through
ethanols, counterstained with thionin (40), and mounted as described above.
RESULTS
Establishment of MIEP-lacZ transgenic mice. The HCMV
MIEP is one of the first viral promoters to be activated upon
viral infection of the cell (7, 57). Since this promoter controls
expression of viral proteins which are integral to subsequent
HCMV promoter activation, activity of the MIEP may ulti-
mately determine viral tissue specificity. To address this issue,
four transgenic mouse lines containing a transgene composed
of the lacZ gene under the control of the MIEP (nt 2670 to
154) (Fig. 1A) were established by the procedures described in
Materials and Methods. All founders gave rise to offspring in
crosses with wild parent nontransgenic mice and transmitted
the introduced gene in Mendelian fashion (approximately 50%
hemizygotes), with copy numbers and restriction patterns as
expected for a single locus. Three of the four founder lines
(TG75ACP, TG1JB, and TG2JB) were analyzed in this study.
FIG. 1. (A) Construct used to generate MIEP-lacZ transgenic mouse lines.
MIEP-lacZ contains a truncated version of the MIEP (nt 2670 to 154, lacking
the modulator and NF1 regions) cloned upstream of the lacZ coding sequence
plus 241 nt of simian virus 40 DNA containing a polyadenylation sequence.
Cleavage sites for restriction enzymes PvuII and PstI are indicated. (B) Southern
blot of three homozygous transgenic mouse lines, demonstrating the presence of
the MIEP-lacZ transgene. Ten micrograms of tail DNA was digested with PvuII
(lanes 1 to 6) or PstI (lanes 7 to 10), run on a 1% agarose gel, transferred to
nitrocellulose, and probed with 32P-labeled MIEP-lacZ transgene DNA. Control
lanes contained 10 mg of normal mouse tail DNA plus 10 (lane 1) or 1 (lanes 2
and 7) genomic equivalent of MIEP-lacZ transgene fragment. Lane 3 contained
10 mg of nontransgenic mouse tail DNA.
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Southern analysis performed on genomic DNA from these
mice, digested with the restriction enzyme PstI or PvuII, showed
different patterns of DNA restriction fragments, indicating that
each of the lines varied in transgene copy number (1 copy for
TG1JB, 2 copies for TG2JB, and.10 copies for TG75ACP) as
well as integration site (Fig. 1B).
Expression of MIEP-lacZ in transgenic mouse tissues. To
understand how the activation of MIEP determines cell tro-
pism of HCMV, the expression of lacZ in our adult transgenic
mouse tissues was assessed by utilizing both X-Gal and anti-
body directed against the b-galactosidase protein in histo-
chemical and immunocytochemical analyses, respectively. X-
Gal staining was confirmed by immunocytochemical staining
using antibodies to b-galactosidase. Organs were considered
positive for lacZ expression if staining was observed in two or
more lines. Positive organs from different lines displayed iden-
tical patterns of transgene expression; however, when organs
with various degrees of expression were compared between the
lines, the strongest expression was in TG75ACP followed by
TG2JB and TGIJB.
Transgenic mice containing the MIEP-lacZ transgene dem-
onstrated expression in 19 of 29 organs (Table 1). These organs
included the brain, spinal cord, esophagus, stomach, pancreas,
kidney, bladder, testes, ovary, spleen, salivary gland, thymus,
bone marrow, cartilage, skin, and striated, cardiac, and smooth
muscles. Infrequently, sporadic cells positive for lacZ expres-
sion were also observed in the thyroid and adrenal glands.
However, these tissues were considered negative for expres-
sion because the positive sporadic cells probably represented
the occasional blood cells trapped in these tissues. In addition,
lacZ staining was not consistently observed in the small intes-
tines of transgenic mice. Only the TG75ACP line demonstrat-
ed staining in the small bowel, which may represent differen-
tial expression because of the site of integration. Therefore,
this organ was considered negative for transgene expression.
Tissues which were consistently negative for lacZ staining in-
cluded the lung, liver, colon, peripheral blood, and peritoneal
macrophages. Similarly, all tissues tested from nontransgenic
control animals were negative for lacZ staining.
MIEP-lacZ expression in the CNS. The central nervous sys-
tem (CNS) is a major target for CMV, especially in patients
with AIDS (16, 31, 35). In these patients, virus infection fre-
quently causes encephalitis and retinitis (21, 58). Histologic
examination of brain tissues from these individuals indicates
that HCMV is capable of infecting most CNS cells, including
neurons, astrocytes, and endothelial cells (59). Examination of
CNS tissue from MIEP-lacZ transgenic mice revealed expres-
sion of lacZ in the forebrain, midbrain, and hindbrain and in
the choriod plexus of the lateral and fourth ventricles as well as
limbic brain structures (Fig. 2B through O). Additionally,
staining was detected in the retina (Fig. 2A) and neuronal
perikarya of the spinal cord (data not shown).
The most intense staining was observed in cells which by
morphology and location resemble neurons of the hindbrain
corresponding to the brain stem and cerebellum (Fig. 2C and
G). Brain stem regions expressing lacZ included the locus
coeruleus, the dorsal raphae nucleus, the reticulotegmented
nucleus of the pons, and the inferior olive (Fig. 2C, D, E, and
F). X-Gal staining in the cerebellum was primarily confined to
cells resembling Purkinje cells (Fig. 2G).
lacZ expression in the forebrain regions was scattered within
the neuronal perikarya of the frontal cortex as well as in a
dense concentration of cells in the olfactory nucleus and the
islands of Calleja (Fig. 2H and I). Cells resembling neurons in
the inferior colliculus and the central gray and ventral tegmen-
tal areas of the midbrain also demonstrated lacZ expression
(Fig. 2J, K, L, and M). b-Galactosidase activity was also ob-
served in the limbic brain regions, which included the dentate
gyrus and hippocampus (Fig. 2N and O). In the dentate gyrus,
transgene expression was confined to granule cell somata in
both the suprapyramidal and infrapyramidal blades (Fig. 2N),
whereas in the hippocampus, staining was observed predomi-
nantly in the pyramidal cell layer (Fig. 2O).
The above results indicate that although the CNS is a major
target for MIEP activity, expression is restricted to defined cell
types in these tissues.
MIEP-lacZ expression in the genitourinary system. In indi-
viduals with acute disease, HCMV viruria is a common feature
resulting from infection of the renal tract (4, 45). Examination
of the kidneys from these patients commonly reveals the pres-
ence of virus in the collecting tubules and proximal tubules
near cortical areas (15). Similarly, we consistently observed
positive lacZ expression in the ductile epithelium of the kid-
neys (Fig. 3F and G) and in the arterioles of the glomeruli (Fig.
3G) of our transgenic mice. HCMV is also frequently associ-
ated with infections in the reproductive organs (28, 32, 53).
The virus is reported to infect mature sperm in humans (18).
Examination of transgenic mouse testes revealed the presence
of b-galactosidase activity in interstitial Leydig’s cells and ma-
ture sperm cells in seminiferous tubules (Fig. 3H). Expression
TABLE 1. HCMV MIEP-directed expression of the
lacZ gene in transgenic mouse lines
System and organ
Expression in transgenic mouse lines:
TG75ACP TG1JB TG2JB
Neural
Brain 1 1 1
Eye 1 1 2
Spinal cord 1 1 1
Respiratory
Lung 2 2 2
GI tract
Esophagus 1 1 1
Stomach 1 2 1
Duodenum 2 2 2
Ileum 2 2 2
Jejunum 2 2 2
Colon 2 2 2
Liver 2 2 2
Pancreas 1 1 1
Genitourinary
Kidney 1 1 1
Bladder 1 1 1
Testes 1 1 1
Ovary 1 1 2
Lymphoid and blood
Lymph node 1 2 2
Spleen 1 1 1
Salivary gland 1 1 1
Thymus 2 1 1
Blood 2 2 2
Bone marrow 1 1 1
Muscle, cartilage, and skin
Cartilage 1 1 1
Striated muscle 1 1 1
Cardiac muscle 1 1 1
Smooth muscle 1 1 1
Skin 1 1 1
Endocrine
Thyroid 1 2 2
Adrenal 2 1 2
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of lacZ in ovaries was restricted to theca cells of the ovarian
corpus luteum (Fig. 3I).
MIEP-lacZ expression in the digestive tract. The epithelial
cells of the gastrointestinal (GI) tract are a common site for
HCMV infection (8, 54). The virus is most commonly found in
the colon, followed by the esophagus, rectum, and small bowel.
Examination of the GI tracts of our transgenic mice revealed
consistent staining for MIEP-lacZ in epithelial cells in the
esophagus (Fig. 3A) and stomach (Fig. 3B). All other portions
of the GI tract were consistently negative for lacZ expression.
FIG. 2. lacZ expression in MIEP transgenic mouse CNS tissues. (A) Paraffin-embedded tissue section of retina stained indirectly for b-galactosidase activity, using
biotinylated anti-b-galactosidase antibody detected with AEC. Rods and cones of the retina show positive (red) staining. Magnification, 3220. (B through O) Sagittal
brain cryosections from MIEP transgenic mice stained directly for b-galactosidase activity, with positive cells giving a blue stain. (B) Region of the choroid plexus, with
staining specific only to ependymal cells. Magnification,3220. (C) Expression in neuronal cells of the locus coeruleus. Magnification,3140. (D) Dorsal raphae nucleus.
Magnification, 325. (E) Reticulotegmented nucleus of the pons (magnification, 325) and (F) inferior olive (magnification, 343). (G) Positive Purkinje cells in the
cerebellum. Magnification, 3220. (H) Expression in the neuronal perikarya of the frontal cortex (magnification, 346) and (I) islands of Calleja (magnification, 346).
(J and K) Low- and high-power photomicrographs showing positive staining in the inferior colliculus. Magnification, 320 and 46, respectively. (L) The central gray
matter (magnification, 344) and (M) ventral tegmented midbrain (magnification, 320). (N) Expression in neurons of the dentate gyrus (magnification, 3240) and (O)
hippocampus (magnification, 3160).
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FIG. 3. lacZ expression in MIEP transgenic mouse tissues of the digestive system (A to E), genitourinary system (F to I), and muscle (J to L), skin (M), cartilage
(N), and bone (O). Cryosections of MIEP-lacZ transgenic tissues were stained directly for b-galactosidase activity, with positive cells appearing blue. (A) Expression
in epithelial cells lining the esophagus (magnification, 350) and (B) stomach (magnification, 3100). (C) Expression in ductile epithelial cells in the salivary gland
(magnification, 350) and (D) exocrine cells in the pancreas (magnification, 3100). (E) Gelatin-embedded thick section of pancreas indirectly stained with anti-b-
galactosidase antibody detected with DAB. Positive (brown) staining is seen in the exocrine cells as well as cells in the islets of Langerhans (arrow). Magnification,3200.
(F) Expression in epithelial cells of the renal tubules (arrow) and arterioles (arrowhead) of the kidney glomeruli. Magnification, 3100. (G) Kidney section stained as
described for panel E, showing expression in the glomeruli (arrow) and renal tubules. Magnification, 330. (H) Expression in Leydig’s cells (arrowhead) and spermatids
(arrow) in the testis (magnification, 3140) and (I) theca cells (arrow) in the ovary (magnification, 3100). Positive expression in (J) striated (magnification, 350), (K)
cardiac (magnification, 3120), and (L) smooth (magnification, 350) muscle fibers. (M) Expression in skin epidermis (magnification, 3160), (N) condrocytes in the
cartilage of the sternum (magnification, 3160), and (O) bone marrow (magnification, 3100).
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Since HCMV is associated with the salivary glands (9) and
pancreas (20), as well as the GI tract, we also examined these
organs of the transgenic mice for MIEP-lacZ expression. The
results revealed consistent expression in the ductile epithelium
of the salivary gland (Fig. 3C) and in a subset of exocrine cells
in the pancreas (Fig. 3D) as well as in defined cells in the islets
of Langerhans (Fig. 3E).
MIEP-lacZ expression in muscle, bone, cartilage, and skin.
HCMV less frequently infects human muscles, bone, and skin
(26, 52, 56). In view of this, we examined these tissues in our
transgenic mice for lacZ expression. Interestingly, we detected
strong expression in skeletal and cardiac muscles. However,
only a subset of muscle fibers were positive for lacZ expression
(Fig. 3J and K). lacZ expression was also detected in aortic
smooth muscle (Fig. 3L). Transgene expression was also de-
tected in the epidermis as well as in cells lining the hair follicles
(Fig. 3M). Examination of cartilaginous and bone tissues re-
vealed lacZ expression in condrocytes in the sternum cartilage
(Fig. 3N) and sporadic cells in the bone marrow (Fig. 3O).
DISCUSSION
In this study, we demonstrated that the HCMV MIEP was
transcriptionally active in multiple organs of transgenic mice.
Expression within these organs was restricted to specific cell
types in highly differentiated tissues. These results contrast
with the results of previous transgenic studies (10, 43) which
suggest that the MIEP is a pan-specific promoter in all tissues
and cells. Importantly, the majority of tissues and cell types
which display MIEP activity parallel tissues naturally infected
by HCMV in the human host.
Previous studies with HCMV-MIEP transgenic animals uti-
lized various portions of the MIEP to examine tissue-specific
expression. Schmidt et al. (43), using a construct containing
MIEP sequences from nt 2585 to 214, observed expression in
24 of 28 tissues in transgenic mice. The greatest amount of
expression was detected in heart, brain, kidney, and testis tis-
sues. These observations are similar to expression patterns in
our transgenic mice, with the exception of those for the pan-
creas and striated muscle. Expression in the latter tissue was
also observed in transgenic mice containing a construct with
MIEP sequences from nt 2524 to 155 (10). Together, these
observations suggest that sequences between nt 214 and 155
alter expression in striated muscle and may determine expres-
sion in the pancreas, although the latter tissue was not exam-
ined by Furth et al. (10).
Although our observations together with those of the studies
above indicate that the MIEP is active in a variety of organs,
histologic examinations of these tissues indicate that the pro-
moter exhibits exquisite cellular specificity. For example, in
striated and cardiac muscle only a subset of fibers were positive
for expression. Tissues such as striated muscle are composed of
multiple elements, including red, intermediate, and white fi-
bers. MIEP activity in this tissue may reflect the specificity of
this promoter for particular fiber types. Interestingly, only a
minor subset of muscle fibers was observed with positive ex-
pression in the tongue of developing embryos (2). While these
findings contrast with the ability of the MIEP to be active in the
majority of cell types in vitro, the restricted expression in trans-
genic mice may relate to differences in both the differentiation
and replicative states of the cells in culture.
The HCMV MIEP contains multiple transcription factor
binding sites, the majority of which constitute signal-regulated
elements. A number of cellular transcription factors known to
interact with the MIEP include SP-1, NF-kB, YY-1, ATF/
CREB, AP-1, and RAR-RXR family members (11–14, 39, 41,
48). The variety of transcription factors which bind the MIEP
may reflect the diversity of tissues in which the promoter is
active and ultimately productively infected by the virus. A
number of these transcription factors which interact with the
MIEP are regulated through signal transduction factors, such
as NF-kB, ATF/CREB, AP-1, and RAR-RXR family members
(1, 11–13, 16, 19, 39, 41, 48). Both direct and indirect cell
signal-mediated regulatory interactions are likely to be in-
volved in regulating the restricted expression of the MIEP in
different tissues. Therefore, signaling pathways may be a fun-
damental mechanism responsible for cell type-restricted pat-
terns of MIEP expression observed in vivo. Clearly, these path-
ways operate during embryogenesis, and MIEP expression is
highly specific and regulated in embryonic tissues (2, 23).
The tissues targeted for expression by the MIEP relate very
well to the various organ diseases associated with HCMV in-
fection. For example, transgene expression detected in brain,
eye, spinal cord, esophagus, stomach, pancreas, and adrenal
gland tissues correlates highly with HCMV-induced encepha-
litis, retinitis, esophagitis, pancreatitis, and adrenalitis. Simi-
larly, MIEP activity in the salivary gland, thymus, skin, carti-
lage, muscle, gonads, and spleen corresponds to sites of natural
infection by HCMV. MIEP expression was also detected in
kidney ductile epithelium and epithelial cells lining the blad-
der. The expression may parallel viral infection of these tissues
and explain the high amounts of HCMV in urine samples. In
addition, specific cells in the bone marrow were also found to
express the MIEP-lacZ transgene. Although the cells in this
hematopoietic organ could not be identified, this tissue is con-
sidered to be a potential reservoir of HCMV (24, 29).
Recently, Koedood et al. (23) reported expression of a sim-
ilar transgene construct in the CNS of developing mouse em-
bryos. In these studies MIEP expression was predominantly
detected in cells of the developing CNS vasculature, hindbrain,
choroid plexus, and subependymal brain regions. We have also
observed similar patterns of MIEP expression in the develop-
ing embryos of our transgenic mice (2). By morphology and
location in the developing fetal brain, the expressing cell types
include endothelial, epithelial, and neuronal cells. MIEP ex-
pression was also observed in similar regions and cell types in
adult transgenic mouse brains, with the exception of the en-
dothelial cells. Interestingly, adult transgenic mice demon-
strate MIEP expression in increased numbers of cells morpho-
logically resembling neurons. Although some differences are
observed in embryonic and adult MIEP expression, all of the
brain regions and cell types are potential targets for HCMV
infection (58).
Interestingly, we observed a lack of transgene expression in
the intestine, liver, and lung, organs commonly associated with
HCMV infection (22). The most obvious explanation for the
absence of MIEP activity in these tissues is the requirement of
this promoter for other viral or virally modified host factors.
The viral factors may include structural components of the
virion or low-level production of IE proteins which have been
shown to activate the MIEP (reviewed in reference 14 and 27).
Alternatively, HCMV disease may involve sites of tissue re-
generation in which the cells revert to a fetal-like phenotype
that is susceptible to HCMV infection. This hypothesis is sup-
ported by the fact that we and others (2, 23) have observed
MIEP expression in a subset of cells in the lungs and livers of
developing embryos.
Smooth muscle was another significant tissue demonstrating
expression of the transgene. HCMV infection of this tissue is
associated with the development of atherosclerosis (30) and
restenosis (47). Both diseases are characterized by the exces-
sive proliferation of smooth muscle cells in the vessels. Asso-
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ciation of the HCMV IE86 protein with p53 is implicated in
the development of restenosis lesions (47). Recently, we have
developed transgenic mice which direct the expression of IE86
in smooth muscle tissues (unpublished observation). These
mice will provide an ideal model to examine the role of HCMV
in these disease processes.
In conclusion, we have completed a full characterization of
the organs and cell types targeted for expression by the HCMV
MIEP. Our results indicate that although the promoter was
active in multiple organs, expression was restricted to specific
cell types. The restricted expression of the MIEP in specific cell
types and tissues may make this promoter useful for targeting
the expression of genes in specific genetic diseases.
ACKNOWLEDGMENTS
Supported by grants from the National Institutes of Health to J.A.N.
(CA50151). P.G. is a Scholar of the Leukemia Society of America.
We thank H. Meyers for performing Southern blots and M. Moody
for assistance with scientific illustrations.
REFERENCES
1. Angulo, A., C. Suto, M. F. Boehm, R. A. Heyman, and P. Ghazal. 1995.
Retinoid activation of retinoic acid receptors but not retinoid X receptors
promotes cellular differentiation and replication of human cytomegalovirus
in embryonal cells. J. Virol. 69:3831–3837.
2. Baskar, J. F., P. Smith, G. Ciment, S. Hoffmann, C. Tucker, D. J. Tenney,
A. M. Colberg-Poley, J. A. Nelson, and P. Ghazal. 1996. Developmental
analysis of the cytomegalovirus enhancer in transgenic animals. J. Virol.
70:3215–3226.
3. Boshart, M., F. Weber, G. Jahn, K. Dorsch-Hasler, B. Fleckenstien, and W.
Schaffner. 1985. A very strong enhancer is located upstream of an immedi-
ate-early gene of human cytomegalovirus. Cell 41:521–530.
4. Cameron, J., R. J. Rigby, A. G. van Deth, and J. J. B. Petrie. 1982. Severe
tubulo-interstitial disease in a renal allograft due to cytomegalovirus infec-
tion. Clin. Nephrol. 18:321–325.
5. Chang, Y. N., S. Crawford, S. Stall, D. R. Rawlins, K. T. Jeang, and G. S.
Hayward. 1990. The palindromic series I repeats in the simian cytomegalo-
virus major immediate-early promoter behave as both strong basal enhancers
and cyclic AMP response elements. J. Virol. 64:264–277.
6. Chee, M. S., A. T. Bankier, S. Beck, R. Bohni, C. M. Brown, R. Cerny, T.
Horsnell, C. A. Hutchinson III, T. Kouzarides, J. A. Martignetti, E. Preddie,
S. C. Satchwell, P. Tomlinson, K. M. Weston, and B. G. Barrell. 1990.
Analysis of the protein-coding content of the sequence of human cytomeg-
alovirus strain AD169. Curr. Top. Microbiol. Immunol. 154:125–169.
7. DeMarchi, J. M., C. A. Schmidt, and A. S. Kaplan.1980. Pattern of transcription
of human cytomegalovirus in permissively infected cells. J. Virol. 35:277–286.
8. Diethelm, A. G., I. Gore, L. T. Ch’ien, W. A. Sterling, and J. M. Morgan.
1976. Gastrointestinal hemorrhage secondary to cytomegalovirus after renal
transplantation. A case report and review of the problem. Am. J. Surg. 131:
371–374.
9. Farber, S., and S. G. Wolback. 1932. Intranuclear and cytoplasmic inclusions
(‘‘protozoan-like bodies’’) in the salivary glands and other organs of infants.
Am. J. Pathol. 8:123–135.
10. Furth, P. A., L. Hennighausen, C. Baker, B. Beatty, and R. Woychick. 1991.
The variability in activity of the universally expressed human cytomegalovi-
rus immediate early gene 1 enhancer/promoter in transgenic mice. Nucleic
Acids Res. 19:6205–6208.
11. Ghazal, P., C. DeMattei, E. Giulietti, S. A. Kliewer, K. Umesono, and R. M.
Evans. 1992. Retinoic acid receptors initiate induction of the cytomegalo-
virus enhancer in embryonal cells. Proc. Natl. Acad. Sci. USA 89:7630–7634.
12. Ghazal, P., H. Lubon, and L. Henninghausen. 1988. Specific interactions
between transcription factors and the promoter-regulatory region of the
human cytomegalovirus major immediate-early gene. J. Virol. 62:1076–1079.
13. Ghazal, P., H. Lubon, and L. Henninghausen. 1988. Multiple sequence-
specific transcription factors modulate cytomegalovirus enhancer activity in
vitro. Mol. Cell. Biol. 8:1809–1811.
14. Ghazal, P., and J. A. Nelson. 1993. Transcription factors and viral regulatory
proteins as potential mediators of human cytomegalovirus pathogenesis, p.
360–383. In Y. Becker, G. Darai, and E.-S. Huang (ed.), Molecular aspects
of human cytomegalovirus diseases. Springer-Verlag, Berlin.
15. Gnann, J. W., Jr., J. Ahlmen, C. Svalander, L. Olding, M. B. A. Oldstone,
and J. A. Nelson. 1988. Inflammatory cells in transplant kidneys are infected
by human cytomegalovirus. Am. J. Pathol. 132:239–248.
16. Haymaker, W., B. R. Girdany, J. Stephens, R. D. Lillie, and G. H. Fetterman.
1954. Cerebral involvement with advanced periventricular calcification in
generalized cytomegalic inclusion disease in the newborn. J. Neuropathol.
Exp. Neurol. 13:562–586.
17. Hogan, B., F. Constatini, and E. Lacy. 1986. Manipulating the mouse em-
bryo. A laboratory manual, p. 153–182. Cold Spring Harbor Laboratory,
Cold Spring Harbor, N.Y.
18. Huang, E.-S., M. G. Davis, J. F. Baskar, and S. M. Huong. 1985. Molecular
epidemiology and oncogenicity of human cytomelovirus, p. 323–344. In C. C.
Harris (ed.), Biochemical and molecular epidemiology of cancer. Abbott-
UCLA Symposium. Alan R. Liss, Inc., New York.
19. Hunninghake, G. W., M. M. Monick, B. Liu, and M. F. Stinski. 1989. The
promoter regulatory region of the major immediate-early gene of human
cytomegalovirus responds to T-lymphocyte stimulation and contains func-
tional cyclic AMP-response elements. J. Virol. 63:3026–3033.
20. Jenson, A. B., H. S. Rosenberg, and A. L. Notkins. 1980. Pancreatic islet cell
damage in children with fatal viral infections. Lancet ii:354–358.
21. Kennedy, P. G., D. A. Newsome, J. Hess, O. Narayan, D. L. Suresch, W. R.
Green, and R. C. Gallo. 1986. Cytomegalovirus but not HTLV-III detected
by in situ hybridization in retinal lesions in patients with AIDS. Br. Med. J.
293:162–164.
22. Klemola, E., R. Stenstrom, and R. von Essen. 1972. Pneumonia as a clinical
manifestation of cytomegalovirus infection in previously healthy adults.
Scand. J. Infect. Dis. 4:7–10.
23. Koedood, M., A. Fichtel, P. Meier, and P. J. Mitchell. 1995. Human cyto-
megalovirus (HCMV) immediate-early enhancer/promoter specificity during
embryogenesis defines target tissues of congenital HCMV infection. J. Virol.
69:2194–2207.
24. Kondo, K., H. Kaneshima, and E. S. Mocarski. 1994. Human cytomegalo-
virus latent infection of granulocyte-macrophage progenitors. Proc. Natl.
Acad. Sci. USA 91:11879–11883.
25. Kothari, S., J. Baille, J. G. Sissons, and J. H. Sinclair. 1991. The 21bp repeat
element of the human cytomegalovirus major immediate-early enhancer is a
negative regulator of gene expression in undifferentiated cells. Nucleic Acids
Res. 19:1767–1771.
26. Lee, J. Y.-Y. 1989. Cytomegalovirus infection involving skin in immunocom-
promised hosts. A clinicopathologic study. Am. J. Pathol. 92:96–100.
27. Liu, B., and M. F. Stinski. 1992. Human cytomegalovirus contains a tegu-
ment protein that enhances transcription from promoters with upstream
ATF and AP-1 cis-acting elements. J. Virol. 66:4434–4444.
28. LiVolsi, V. A., and M. J. Merino. 1979. Cytomegalovirus infection of ovarian
thecoma. Arch. Pathol. Lab. Med. 103:653–654.
29. Maciejewski, J. P., E. E. Brenning, R. E. Donahue, E. S. Mocarski, R. E.
Young, and S. C. St. Jeor. 1992. Infection of hematopoietic progenitor cells
by human cytomegalovirus. Blood 80:170–178.
30. Melnick, J. L., E. Adam, and M. E. Debakey. 1993. Cytomegalovirus and
atherosclerosis. Eur. Heart J. 14(Suppl.):30–38.
31. Morgello, S., E. S. Cho, S. Nielsen, O. Devinsky, and C. K. Petito. 1987.
Cytomegalovirus encephalitis in patients with acquired immunodeficiency
syndrome. Hum. Pathol. 18:289–297.
32. Mueller, N., J. Hinkula, and B. Wahren. 1988. Elevated antibody titers
against cytomegalovirus among patients with testicular cancer. Int. J. Cancer
41:399–403.
33. Nelson, J. A., J. W. Gnann, Jr., and P. Ghazal. 1990. Regulation and tissue-
specific expression of human cytomegalovirus. Curr. Top. Microbiol. Immu-
nol. 154:75–100.
34. Nelson, J. A., and M. Groudine. 1986. Transcriptional regulation of the
human cytomegalovirus major immediate-early gene is associated with in-
duction of DNase I-hypersensitive sites. Mol. Cell. Biol. 6:452–461.
35. Nelson, J. A., C. Reynolds-Kohler, M. B. A. Oldstone, and C. A. Wiley. 1988.
HIV and CMV coinfect brain cells in patients with AIDS. Virology 165:
286–290.
36. Nelson, J. A., C. Reynolds-Kohler, and B. Smith. 1987. Negative and positive
regulation by a short segment in the 59-flanking region of the human cyto-
megalovirus major immediate-early gene. Mol. Cell. Biol. 7:4125–4129.
37. Nilaver, G., and G. P. Kozlowski. 1989. Comparison of the PAP and ABC
immunocytochemical techniques, p. 199–215. In G. R. Bullock and P.
Petrusz (ed.), Techniques in immunocytochemistry, vol. 4. Academic Press,
New York.
38. Nilaver, G., L. L. Muldoon, R. A. Kroll, M. A. Pagel, X. O. Breakefield, B. L.
Davidson, and E. A. Neuwelt. 1995. Delivery of herpesvirus and adenovirus
to nude rat intracerebral tumors after osmotic blood-brain barrier disrup-
tion. Proc. Natl. Acad. Sci. USA 92:9829–9833.
39. Niller, H. H., and L. Hennighausen. 1990. Phytohemagglutinin-induced ac-
tivity of cyclic AMP (cAMP) response elements from cytomegalovirus is
reduced by cyclosporine and synergistically enhanced by cAMP. J. Virol. 64:
2388–2391.
40. Roque, A. L., N. A. Jafarey, and P. Coulter. 1965. A stain for the histochem-
ical demonstration of nucleic acids. Exptl. Mol. Pathol. 4:266–274.
41. Sambucetti, L. C., J. M. Cherrington, G. W. G. Wilkinson, and E. S.
Mocarski. 1989. NF-kB activation of the cytomegalovirus enhancer is medi-
ated by a viral transactivator and by T cell stimulation. EMBO J. 8:4251–
4258.
42. Sanes, J. R., L. R. Rubenstein, and J. F. Nicolas. 1986. Use of a recombinant
retrovirus to study post-implantation cell lineage in mouse embryos. EMBO
J. 5:3133–3142.
VOL. 70, 1996 CMV ENHANCER IN TRANSGENIC MICE 3213
43. Schmidt, E. V., G. Christoph, R. Zeller, and P. Leder. 1990. The cytomeg-
alovirus enhancer: a pan-active control element in transgenic mice. Mol.
Cell. Biol. 10:4406–4411.
44. Shelbourn, S. L., S. K. Kothari, J. G. Sissons, and J. H. Sinclair. 1989.
Repression of human cytomegalovirus gene expression associated with a
novel immediate-early regulatory region binding factor. Nucleic Acids Res.
17:9165–9171.
45. Shorr, R. I., W. L. Longo, T. D. Oberley, M. J. Bozdech, and D. L. Walker.
1987. Cytomegalovirus-associated tubulointerstitial nephritis in an allogenic
bone marrow transplant recipient. Ann. Intern. Med. 107:351–352.
46. Southern, E. M. 1975. Detection of specific sequences among DNA frag-
ments separated by gel electrophoresis. J. Mol. Biol. 98:503–517.
47. Speir, E., R. Modali, E.-S. Huang, M. B. Leon, F. Shawl, T. Finkel, and S. E.
Epstein. 1994. Potential role of human cytomegalovirus and p53 interaction
in coronary restenosis. Science 265:391–394.
48. Stamminger, T., H. Fickenscher, and B. Fleckenstein. 1990. Cell type-spe-
cific induction of the major immediate-early enhancer of human cytomega-
lovirus by cyclic AMP. J. Gen. Virol. 71:105–113.
49. Stenberg, R. M., A. S. Depto, J. Fortney, and J. A. Nelson. 1989. Regulated
expression of early and late RNAs and proteins from the human cytomeg-
alovirus immediate-early gene region. J. Virol. 63:2699–2708.
50. Stenberg, R. M., D. R. Thomsen, and M. F. Stinski. 1984. Structural analysis
of the major immediate-early gene of human cytomegalovirus. J. Virol. 49:
190–199.
51. Stenberg, R. M., P. R. Witte, and M. F. Stinski. 1985. Multiple spliced and
unspliced transcripts from human cytomegalovirus immediate-early region
two and evidence for a common initiation site within immediate-early region
one. J. Virol. 56:665–675.
52. Sterner, G., B. O. Agell, B. Sahren, and A. Espmark. 1970. Acquired cyto-
megalovirus infection in older children and adults. Scand. J. Infect. Dis. 2:
95–103.
53. Subietas, A., L. J. Deppisch, and J. Astarloa. 1977. Cytomegalovirus oopho-
ritis: ovarian cortical necrosis. Hum. Pathol. 8:285–292.
54. Teixidor, H. S., C. L. Honig, E. Norsoph, S. Albert, J. A. Mouradian, and
J. P. Whalen. 1987. Cytomegalovirus infection of the alimentary canal: ra-
diologic findings with pathologic correlation. Radiology 163:317–323.
55. Thomsen, D. R., R. M. Stenberg, W. F. Goins, and M. F. Stinski. 1984.
Promoter-regulatory region of the major immediate-early gene of human
cytomegalovirus. Proc. Natl. Acad. Sci. USA 81:659–663.
56. Ward, P. H., J. R. Lindsay, and N. E. Warner. 1965. Cytomegalic inclusion
disease affecting the temporal bone. Laryngoscope 75:628–638.
57. Wathen, M. W., and M. F. Stinski. 1982. Temporal patterns of human
cytomegalovirus transcription: mapping the viral RNAs synthesized at im-
mediate-early, early, and late times after infection. J. Virol. 41:462–477.
58. Wiley, C. A., and J. A. Nelson. 1988. Role of human immunodeficiency virus
and cytomegalovirus in AIDS encephalitis. Am. J. Pathol. 133:73–81.
59. Wiley, C. A., R. D. Schrier, F. J. Denaro, J. A. Nelson, P. W. Lampert, and
M. B. Oldstone. 1986. Localization of cytomegalovirus proteins and genome
during fulminate central nervous system infection in an AIDS patient. J.
Neuropathol. Exp. Neurol. 45:127–139.
3214 BASKAR ET AL. J. VIROL.


